ADVANCED SOLID TUMORS

This study allows 120 patients with advanced solid tumors who are already benefiting from the experimental immunotherapy drug spartalizumab to continue receiving it. The main goal is to monitor the drug's long-term safety and side effects. It is a follow-up for patients who parti…

This is a first-in-human study to find a safe dose and see if a new oral drug, Debio 0123, can help control advanced solid tumors. It will enroll about 66 adults whose cancer has grown despite standard treatments. The study has two parts: first to find the right dose, and then to…

This is the first study in people to test the safety and early effectiveness of an investigational drug called ABBV-400 for adults with advanced solid tumors that have stopped responding to standard treatments. The trial will find the best dose of ABBV-400 given alone and will al…

This study tested pembrolizumab, an immunotherapy drug, in people with advanced solid tumors who had already tried standard treatments that stopped working. Researchers enrolled 1,609 participants with various cancers including anal, cervical, lung, and thyroid cancers to see how…

This study is testing a new combination of two drugs, AK127 and AK112, for people with advanced solid tumors that have stopped responding to standard treatments. The main goals are to find a safe dose and see if the combination can shrink tumors. It will involve about 216 adults …

This is an early-stage safety study testing a new mRNA-based cancer therapy called mRNA-4106. It is being given alone and in combination with standard immunotherapy drugs to 57 patients with various advanced solid tumors. The main goal is to find a safe dose and understand the si…

This is a first-in-human study to find a safe dose and see how the body processes a new oral drug called ATV-1601. It is being tested in adults with advanced solid tumors, including certain breast cancers, that have a specific genetic change called an AKT1 E17K mutation. The main…

This early-stage study aims to determine the safety and appropriate dosage of a new experimental cancer drug called FF-10850. The trial will enroll approximately 96 adults with advanced solid tumors that have not responded to standard treatments, including ovarian cancer and Merk…

This early-stage study is testing a new oral immunotherapy drug called BAY2965501 in people with advanced solid tumors that have spread and are hard to treat. Researchers want to find the safest dose and see how the body handles the drug, both alone and combined with other cancer…

This is the first study to test a new antibody drug called PRL3-ZUMAB in people. The goal is to find a safe dose for patients with advanced solid tumors or blood cancers that have stopped responding to standard treatments. Researchers will give increasing doses to small groups of…

This is a first-in-human study to check the safety and early effectiveness of a new drug, QTX3544, for people with advanced solid tumors that have a specific genetic change called KRAS G12V. The trial will test QTX3544 given alone or combined with an existing cancer drug, cetuxim…

This study is testing a new combination of two drugs, BAT8008 and BAT1308, for people with advanced solid tumors that have not responded to standard treatments. The main goals are to find the safest and most effective dose and to see if the combination can help shrink or control …

This is the first study in people to test a new experimental drug called VVD-130850, which blocks a protein called STAT3 that helps cancer grow. The main goal is to find a safe dose and see how the body handles the drug, both alone and combined with an existing immunotherapy. It …

This is an early-stage study to test the safety and find the right dose of a new drug called HRS-6209 for people with advanced solid tumors. It will involve 56 patients whose cancer has progressed despite standard treatments. The main goals are to see how much of the drug the bod…

This early-stage trial is testing the safety and effectiveness of a drug called sotorasib, both by itself and combined with other cancer therapies. It is for adults with advanced solid tumors that have a specific genetic change known as the KRAS p.G12C mutation. The main goal is …

This study is testing if adding an experimental drug called NP137 to standard immunotherapy helps patients with advanced solid tumors. It focuses on people whose cancer has stopped responding well to their current immunotherapy. The goal is to see if the combination can better co…

This early-stage study is testing a new drug called INCB177054, given alone or with an immunotherapy drug, in people with advanced solid tumors that have spread or cannot be cured by surgery. The main goals are to find a safe dose and see if the treatment can shrink tumors. It is…

This is the first human study of an experimental drug called ABBV-706 for people with advanced solid tumors that have stopped responding to standard treatments. The main goals are to find a safe dose and see how the body processes the drug, while also checking for early signs tha…

This is the first study in people testing a new drug called AMG 355, both by itself and combined with an existing immunotherapy (pembrolizumab). It aims to find safe doses and see if the treatment helps adults with advanced solid tumors that have stopped responding to standard tr…

This is an early-stage study to test the safety of a new cancer treatment called hV01. The treatment uses a modified virus designed to infect and kill cancer cells while also boosting the immune system. The study will enroll 24 adults with advanced solid tumors that have not resp…

This is the first study in humans of a new immunotherapy drug called BPT567 for people with advanced solid tumors that have stopped responding to standard treatments. The main goals are to find a safe dose, check for side effects, and see how the body processes the drug. Research…

This early-stage study is testing a new immunotherapy drug called BAY 3375968 for people with advanced solid tumors that have not responded to standard treatments. The drug aims to boost the immune system's ability to fight cancer by targeting specific cells that suppress immunit…

This early-stage study is testing a new oral medication called ZN-A-1041 for people with advanced HER2-positive cancers that have spread or returned after treatment. Researchers will give the drug alone or combined with other standard cancer therapies to about 210 participants to…

This is an early-stage study to find a safe dose and see how the body processes a new drug called GDC-6036. It is being tested alone and with other cancer drugs in people with advanced solid tumors, like lung or colorectal cancer, that have a specific genetic change called KRAS G…